DETROIT, Oct. 20 (UPI) — Nearly 87 percent of men who underwent robot-assisted prostate surgery had no recurrence of disease five years later, U.S. researchers found.
Study leader Dr. Mani Menon of Henry Ford Hospital in Detroit, a pioneer in minimally invasive laparoscopic treatment of prostate cancer, and Dr. James Peabody performed all of the robot-assisted surgeries in the study. They say the study period included their own learning curve in using the robot-assisted technique, so results may be difficult to generalize.
The study, published in European Urology journal, involved 1,384 men diagnosed with moderately aggressive prostate cancer who underwent robot-assisted prostate removal from September 2001 to May 2005. Their average age was 60.
The patients were checked for recurrence of their cancer every three months during the first year after surgery, twice during the second year, then annually.
The Henry Ford robot-assisted urology program uses the DA Vince computer-enhanced, minimally invasive surgery system, which enables surgeons to manipulate robotic arms for precise procedures through a series of small incisions and provides 3-D monitoring for the entire surgical team.
“With five-year actuarial biochemical recurrence-free survival outcomes of 86.6 percent, robot-assisted radical prestidigitator appears to confer effective five-year prostate cancer control,” Menon said in a statement.
Copyright 2010 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI’s prior written consent.